Reference entry
Bronchogen (AEDL)
AEDL Tetrapeptide · Bronchial Bioregulator
Overview
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides,…
Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows…
Supports bronchial tissue through gene expression regulation.
Helps maintain respiratory epithelium health.
Regulates protein synthesis in lung tissue.
Mechanism
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides,…
Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows…
Supports bronchial tissue through gene expression regulation.
Research areas
- Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides,…
- Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows…
- Supports bronchial tissue through gene expression regulation.
- Helps maintain respiratory epithelium health.
- Regulates protein synthesis in lung tissue.
Research notes
- Generally well-tolerated
- Minimal side effects reported
- Unusual respiratory symptoms
- Active respiratory emergencies (seek medical care)
- Pregnancy or breastfeeding
Pharmacokinetics
- Bronchogen's tetrapeptide structure allows it to penetrate cell nuclei directly and modulate gene expression epigenetically. Despite its short circulating half-life, it triggers lasting changes in DNA regulation and protein synthesis in bronchial tissue. These epigenetic changes persist long after the peptide itself…
Questions
Can I combine Bronchogen with other respiratory support supplements?
Yes. Bronchogen's epigenetic mechanism complements other approaches. It pairs well with standard respiratory support compounds, though no specific clinical data on combinations exists. Other Khavinson peptides like Chonluten target related respiratory systems synergistically.
How long before I notice respiratory improvements on Bronchogen?
Bronchogen works through gene expression changes that occur during the 10-20 day cycle. Noticeable respiratory improvements typically emerge weeks to months after cycles complete as the epigenetic changes take effect. Results improve with repeated 2-3 cycles yearly for cumulative benefits.